Hope Biosciences Research Foundation Announces Topline Results of Cell Therapy Clinical Trial in Long COVID
Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) today shares topline results of a randomized, placebo-controlled Phase II study ( NCT05126563 ) to evaluate Hope Biosciences’ adipose‑derived allogeneic mesenchymal stem cell therapy (HB-adMSCs) for patients with Post‑COVID‑19 syndrome.
- Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) today shares topline results of a randomized, placebo-controlled Phase II study ( NCT05126563 ) to evaluate Hope Biosciences’ adipose‑derived allogeneic mesenchymal stem cell therapy (HB-adMSCs) for patients with Post‑COVID‑19 syndrome.
- The trial enrolled 79 participants, with 39 subjects in the treatment group and 40 in the placebo group; 34 participants completed the study from the treatment group, and 30 from the placebo group.
- The 26-week study mandated four infusions of 200 million stem cells, for a total of 800 million cells.
- The study announced in this release is made possible in part due to support from The John S. Dunn Foundation.